NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SYNCOMF · data 2026-10-31
Syncom Formulation (India) Ltd.
In plain words
Price: 30.0% below its 52-week high of ₹27.49.
Delivery: 30.1% of traded shares were kept for delivery over the last 10 sessions, against 33.3% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹498 cr |
| Net profit (last 12 months) | ₹86 cr |
| Sales growth, 3 years (yearly) | 29.4% |
| Profit growth, 3 years (yearly) | 56.2% |
At a glance
Promoters 50.6% (unchanged in a year), pledged 0.0%, institutions 2.2%.
P/E 21.1, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 20.2%, ROCE 16.3%, operating margin 16.3%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 56.2% and sales growth 29.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- High return on equity (20.2%).
- Profit grew 56.2% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
12/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 7/30: Delivery 26.9% over the last 20 sessions vs 21.8% in the 40 before (1.23x); shares delivered per day 0.89x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: Net −₹1.35 cr in bulk/block deals over 90 days (0 net buying days, 1 net selling day): more sold than bought.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend
- 30 Sept 26Deal Bulk deal: HRTI PRIVATE LIMITED sold ₹1.35 cr -8.5% next session
- 23 Sept 26Dividend Dividend ₹0.1 (ex-date) -1.8% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 50.57% | 50.57% | 50.57% | 50.57% |
| Foreign institutions (FII) | 2.22% | 0.35% | 0.21% | 0.26% |
| Domestic institutions (DII) | 0.00% | 0.00% | 0.00% | 0.00% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 35.93% | 38.39% | 38.75% | 38.63% |
| Number of shareholders | 4,18,465 | 4,22,114 | 4,31,690 | 4,42,280 |
Common questions
How much do promoters hold in Syncom Formulation (India) Ltd.?
Promoters held 50.57% of Syncom Formulation (India) Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Syncom Formulation (India) Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Syncom Formulation (India) Ltd.'s P/E ratio?
About 21.2, based on the last 12 months' earnings and a price of ₹19.24 (data 2026-10-31).
What is the 52-week high and low of Syncom Formulation (India) Ltd.?
The 52-week high is ₹27.49 and the 52-week low is ₹10.21.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Syncom Formulation (India) Ltd. | ₹19.24 | ₹1,810 cr | 21.2 | — | 20.2% | 16.3% | 0 | +16.0% |
| Hester Biosciences Limited | ₹2,289.3 | ₹1,956 cr | 14.3 | — | 16.5% | 13% | 0.54 | +40.7% |
| Indoco Remedies Limited | ₹208.3 | ₹1,923 cr | 60.1 | 1.9 | -9.7% | -2% | 1.15 | -25.0% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
| Windlas Biotech Ltd. | ₹876.1 | ₹1,810 cr | 28 | — | 12.2% | 13.5% | 0.06 | -8.4% |
| Venus Remedies Limited | ₹1,238.6 | ₹1,646 cr | 13.6 | 2.4 | 16.8% | 14.5% | 0.02 | +182.9% |
Compare SYNCOMF with HESTERBIO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SYNCOMF in NSE Scanner →